X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16) 16
humans (12) 12
female (10) 10
male (10) 10
adult (9) 9
double-blind method (8) 8
middle aged (8) 8
ophthalmology (8) 8
aged (4) 4
dose-response relationship, drug (4) 4
dry eye disease (4) 4
eye diseases (4) 4
symptoms (4) 4
treatment outcome (4) 4
aged, 80 and over (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antibodies, monoclonal - adverse effects (3) 3
dry eye syndromes - drug therapy (3) 3
efficacy (3) 3
gonorrhea (3) 3
lisdexamfetamine dimesylate (3) 3
lymphocyte function-associated antigen-1 - drug effects (3) 3
medicine, general & internal (3) 3
multiple sclerosis (3) 3
neisseria gonorrhoeae (3) 3
pharmacology & pharmacy (3) 3
phenylalanine - analogs & derivatives (3) 3
psychiatry (3) 3
safety (3) 3
statistics & probability (3) 3
adhd (2) 2
adolescent (2) 2
adverse drug reactions (2) 2
analysis (2) 2
antagonist sar 1118 (2) 2
attention - drug effects (2) 2
attention deficit disorder with hyperactivity - drug therapy (2) 2
attention deficit disorder with hyperactivity - psychology (2) 2
care and treatment (2) 2
children (2) 2
clinical ophthalmology (2) 2
clinical trials (2) 2
controlled-trial (2) 2
cytokine (2) 2
deficit hyperactivity disorder (2) 2
dextroamphetamine - administration & dosage (2) 2
dextroamphetamine - adverse effects (2) 2
double-blind (2) 2
dry eye syndromes - physiopathology (2) 2
executive function - drug effects (2) 2
experimental autoimmune encephalomyelitis (2) 2
genetic aspects (2) 2
gepotidacin (2) 2
individuals (2) 2
infection (2) 2
inflammation (2) 2
integrin antagonist (2) 2
lfa-1 (2) 2
lifitegrast (2) 2
mathematics (2) 2
medicine, research & experimental (2) 2
microbiology (2) 2
neurology (2) 2
neuropsychological tests (2) 2
open-label (2) 2
ophthalmic drugs (2) 2
ophthalmic solution 5.0-percent (2) 2
ophthalmic solutions - therapeutic use (2) 2
pharmacokinetics (2) 2
phenylalanine - therapeutic use (2) 2
placebo (2) 2
placebos (2) 2
prospective studies (2) 2
randomized controlled trial (2) 2
risk factors (2) 2
stability (2) 2
studies (2) 2
sulfones - therapeutic use (2) 2
t-cells (2) 2
urogenital (2) 2
young adult (2) 2
5-ht3 (1) 1
abridged index medicus (1) 1
accumulation (1) 1
activation (1) 1
activities of daily living - psychology (1) 1
aerospace medicine (1) 1
agreement (1) 1
algebra (1) 1
alleles (1) 1
alpha monoclonal-antibody (1) 1
altitude sickness - etiology (1) 1
alzheimers disease (1) 1
amino acid oxidoreductases - genetics (1) 1
amino acid oxidoreductases - physiology (1) 1
amino acid substitution (1) 1
amphetamine salts spd465 (1) 1
and commentaries (1) 1
animals (1) 1
antagonism (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Neurology, The, ISSN 1474-4422, 2008, Volume 7, Issue 9, pp. 796 - 804
Journal Article
Sexually Transmitted Infections, ISSN 1368-4973, 07/2017, Volume 93, Issue Suppl 2, p. A11
IntroductionGonorrhoea is currently the second most common bacterial sexually transmitted infection and represents a serious public health threat. The... 
Studies | Gonorrhea
Journal Article
Nature Communications, ISSN 2041-1723, 12/2019, Volume 10, Issue 1, pp. 687 - 15
How innate T cells (ITC), including invariant natural killer T (iNKT) cells, mucosal-associated invariant T (MAIT) cells, and gamma delta T cells, maintain a... 
BET | REGULATOR | ACTIVATION | RNA-SEQ | MULTIDISCIPLINARY SCIENCES | ID PROTEINS | EXPANSION | TERMINAL DIFFERENTIATION | GENE ONTOLOGY | PLZF | T-CELLS | Cell proliferation | Populations | Transcription | Mucosa | Effector cells | Lymphocytes T | Gene expression | Invariants | Heterogeneity | Killer cells | Ribonucleic acids | Lymphocytes | Natural killer cells | Index Medicus
Journal Article
Ophthalmology, ISSN 0161-6420, 2016, Volume 124, Issue 1, pp. 53 - 60
Purpose Lifitegrast is a lymphocyte function–associated antigen-1 antagonist developed to reduce inflammation in dry eye disease (DED). We report the results... 
Ophthalmology | Eye diseases | Care and treatment | Information management
Journal Article
by Aung, T and Ozaki, M and Lee, M.C and Schlotzer-Schrehardt, U and Thorleifsson, G and Mizoguchi, T and Igo, R.P., Jr and Haripriya, A and Williams, S.E and Astakhov, Y.S and Orr, A.C and Burdon, K.P and Nakano, S and Mori, K and Abu-Amero, K and Hauser, M and Li, Z and Prakadeeswari, G and Bailey, J.N and Cherecheanu, A.P and Kang, J.H and Nelson, S and Hayashi, K and Manabe, S.I and Kazama, S and Zarnowski, T and Inoue, K and Irkec, M and Coca-Prados, M and Sugiyama, K and Jarvela, I and Schlottmann, P and Lerner, S.F and Lamari, H and Nilgun, Y and Bikbov, M and Park, K.H and Cha, S.C and Yamashiro, K and Zenteno, J.C and Jonas, J.B and Kumar, R.S.S and Perera, S.A and Chan, A.S.Y and Kobakhidze, N and George, R and Vijaya, L and Do, T and Edward, D.P and Juan Marcos, L. de and Pakravan, M and Moghimi, S and Ideta, R and Bach-Holm, D and Kappelgaard, P and Wirostko, B and Thomas, S and Gaston, D and Bedard, K and Greer, W.L and Yang, Z and Chen, X and Huang, L and Sang, J and Jia, H and Jia, L and Qiao, C and Zhang, H and Liu, X and Zhao, B and Wang, Y.X and Xu, L and Leruez, S and Reynier, P and Chichua, G and Tabagari, S and Uebe, S and Zenkel, M and Berner, D and Mossbock, G and Weisschuh, N and Hoja, U and Welge-Luessen, U.C and Mardin, C and Founti, P and Chatzikyriakidou, A and Pappas, T and Anastasopoulos, E and Lambropoulos, A and Ghosh, A and Shetty, R and Porporato, N and Saravanan, V and Venkatesh, R and Shivkumar, C and Kalpana, N and Sarangapani, S and Kanavi, M.R and Beni, A.N and Yazdani, S and ...
Nature Genetics, ISSN 1061-4036, 2017, Volume 49, Issue 7, pp. 993 - 1004
Exfoliation syndrome (XFS) is the most common known risk factor for secondary glaucoma and a major cause of blindness worldwide. Variants in two genes, LOXL1... 
INDIVIDUALS | RISK LOCI | PSEUDOEXFOLIATION SYNDROME | INFLAMMATORY-BOWEL-DISEASE | METAANALYSIS | POLYMORPHISMS | COMMON SEQUENCE VARIANTS | GENETICS & HEREDITY | GLAUCOMA | BLOOD-PRESSURE | GENOME-WIDE ASSOCIATION | Haplotypes | Humans | Asian Continental Ancestry Group - genetics | Extracellular Matrix - metabolism | Male | Gene Expression Profiling | Mutation, Missense | Amino Acid Oxidoreductases - genetics | Exfoliation Syndrome - ethnology | RNA, Messenger - biosynthesis | Aged, 80 and over | Female | Spheroids, Cellular | Calcium Channels - genetics | Molecular Chaperones - biosynthesis | Eye - metabolism | Genetic Predisposition to Disease | Genome-Wide Association Study | Amino Acid Oxidoreductases - physiology | Molecular Chaperones - genetics | Cell Adhesion | Point Mutation | Alleles | Exfoliation Syndrome - genetics | Amino Acid Substitution | Exfoliatins | Disease susceptibility | Genetic aspects | Analysis | Risk factors | Glaucoma | Genes | Principal components analysis | Cardiovascular disease | Genomes | Biology | Loci | Exfoliation | Studies | Collaboration | Blindness | Alzheimers disease | Index Medicus | Life Sciences | Populations and Evolution | Microbiology and Parasitology | Parasitology | Quantitative Methods | Computer Science | Genetics | Santé publique et épidémiologie | Bioinformatics | Human genetics | Virology
Journal Article
Ophthalmology, ISSN 0161-6420, 2015, Volume 122, Issue 12, pp. 2423 - 2431
Purpose Lifitegrast is an integrin antagonist that decreases T-cell–mediated inflammation associated with dry eye disease (DED). We report the results of... 
Ophthalmology | Eye diseases | Care and treatment | T cells | Ophthalmic drugs | Integrins
Journal Article
Clinical Ophthalmology, ISSN 1177-5467, 01/2018, Volume 12, pp. 263 - 270
To evaluate ocular comfort of lifitegrast ophthalmic solution 5.0% among patients with dry eye disease (DED) in the OPUS-3 trial. OPUS-3 was a multicenter,... 
Drop comfort | OPUS-3 | Dry eye disease | Ocular comfort | Lifitegrast ophthalmic solution 5.0 | Hypothesis testing | Diabetic retinopathy | Cornea | Pain | Eye diseases | FDA approval | Ophthalmology | Preferences | dry eye disease | drop comfort | lifitegrast ophthalmic solution 5.0 | ocular comfort
Journal Article
Clinical Ophthalmology, ISSN 1177-5483, 05/2018, Volume 12, pp. 913 - 914
Nichols KK, Holland E, Toyos MM, et al. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.... 
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 08/2019, Volume 8, Issue 6, pp. 754 - 764
This was a first‐time‐in‐human randomized, double‐blind, single‐center, placebo‐controlled dose‐escalation study to determine the safety, tolerability, and... 
antibiotic | pharmacokinetics | cephalosporin | siderophore | PHARMACOLOGY & PHARMACY | CEFIDEROCOL | 5-HT3 | Clinical trials | Pharmacology | Drug therapy | Drug dosages | Index Medicus
Journal Article
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 10/2016, Volume 32, Issue 10, pp. 1759 - 1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for... 
Dry eye therapy | DED | Corneal inflammatory disease | Eye dryness | Lifitegrast | Integrin antagonist | Dry eye disease | MEDICINE, RESEARCH & EXPERIMENTAL | MEDICINE, GENERAL & INTERNAL | PLACEBO | OPHTHALMIC SOLUTION 5.0-PERCENT | SAR 1118
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 08/2018, Volume 67, Issue 4, pp. 504 - 512
In this phase 2 study, single oral doses of gepotidacin were ≥95% effective for bacterial eradication in culture-proven uncomplicated urogenital gonorrhea. New... 
UNITED-STATES | INFECTIOUS DISEASES | gonorrhea | CEFTRIAXONE | gepotidacin | SUSCEPTIBILITY | MICROBIOLOGY | FUTURE | IMMUNOLOGY | EMERGENCE | TRIAL | urogenital | Neisseria gonorrhoeae | AZITHROMYCIN RESISTANCE | NEISSERIA-GONORRHOEAE | INFECTION | UNTREATABLE GONORRHEA | and Commentaries
Journal Article